Key events, in time order
9% organic sales growth, adjusted EPS up 17.9% YoY; narrowed 2026 guidance weighs on shares
Q2 organic growth 9%, adj EPS up 17.9%; narrowed 2026 guidance weighs, shares down 7.8% after hours
Three firms disclosed Q1 position changes with mixed directions, indicating institutional divergence
Organic sales growth was 2.4% worldwide (1.9% U.S., 3.9% international) in Q1 2026, significantly impacted by cyber incident late in quarter
None yet
None yet
A political trade alert notes a sale of Stryker stock by a representative, indicating a potential shift in holdings.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Stryker makes the implants, surgical tools, and hospital gear that doctors use in operating rooms—think knee replacements, power drills, and stroke-clearing catheters.
Money comes from selling medical devices to hospitals and clinics in ~75 countries; gross margin is 65.17% and net margin 14.43%, with recurring revenue from disposables and reprocessed devices.
Surgeons stick with Stryker's implants and tools because they're trained on them and hospitals trust the brand, but Zimmer Biomet and Medtronic compete hard in orthopedics and neurotech, and pricing pressure from hospital group purchasing is eroding that edge.
Sell (sector percentile 28) — value B, growth B, profitability B, momentum D, revisions C+. Updated daily, sector-relative, identical for every user.
